Introduction {#Sec1}
============

Benzophenanthridine and protopine alkaloids occur in *Macleaya cordata* (Willd) R. Br. and have been investigated for their intriguing bioactivity, such as anticancer, anti-bacterial, insecticidal, and anti-inflammatory effects^[@CR1],[@CR2]^. *Macleaya cordata* is a perennial plant in the family of Papaveraceae, which has been used in folk medicine for the treatment of cervical cancer, thyroid cancer, inflamed wounds, ringworm infection, arthritis, and trichomonas vaginalis^[@CR3],[@CR4]^. In our previous investigation, two pairs of enantiomeric alkaloid dimers (macleayins A and B) with cytotoxicity were isolated from *M*. *cordata* ^[@CR5]^. In our present study, LC-MS- guided fractionation (Fig. [1](#Fig1){ref-type="fig"}) led to the isolation of three pairs of analogous dimers, macleayins F--H (**1**--**3**) biogenetically derived from a benzophenanthridine and protopine alkaloid through C6--C~13′~ linkage. Four possible biogenetic precursors, sanguinarine, chelerythrine, protopine, and allocryptopine (**4**--**7**) were obtained (Fig. [2](#Fig2){ref-type="fig"}). Herein, we reported the isolation, and structural elucidation of new compounds. In addition, the antiproliferative properties and action mechanism were also investigated.Figure 1LC-MS analysis chromatogram of the crude ethanol extract from *M*. *cordata*. Figure 2Structures of compounds **1**--**7** and macleayins A, B.

Results and Discussion {#Sec2}
======================

Structural Elucidation of Compounds 1a/1b--3a/3b {#Sec3}
------------------------------------------------

Macleayin F (**1**) was isolated as white amorphous powder, with the molecular formula of C~41~H~36~N~2~O~9~, deduced from HRESIMS \[M + H\]^+^ (*m/z* 701.2491, calcd for 701.2494), appropriate for 25 degrees of unsaturation. The IR spectrum indicated the presence of ketone carbonyl (1656 cm^−1^), methylenedioxyl group (2792, 941 cm^−1^), and aromatic ring (1616, 1486, 1462 cm^−1^). In the UV spectrum, the absorption maxima at 227 and 287 nm were detected. The HRESIMS/MS spectrum exhibited the fragment peak at *m/z* 348.1281 assigned to chelerythrine^[@CR6]^. The ^1^H NMR (Table [1](#Tab1){ref-type="table"}) spectrum revealed the presence of three AB spin systems of aromatic protons in *ortho*-position ((*δ* ~H~ 6.68 (br d, *J* = 7.3 Hz, H-9) and 7.23 (br d, *J* = 7.3 Hz, H-10), 7.46 (d, *J* = 8.5 Hz, H-12) and 7.61 (d, *J* = 8.5 Hz, H-11), 6.97 (br d, *J* = 8.0 Hz, H-11′) and 7.50 (br s, H-12′)), four aromatic protons in singlet (*δ* ~H~ 7.05, 6.85, 6.83, and 6.21), two sp^3^ methine protons (*δ* ~H~ 5.13 (d, *J* = 9.0 Hz) and 4.59 (d, *J* = 9.0 Hz)), as well as three methylenedioxyl groups ((*δ* ~H~ 5.99 (d, *J* = 1.1 Hz), 5.96 (d, *J* = 1.1 Hz), 5.91 (d, *J* = 1.1 Hz), 5.83 (d, *J* = 1.1 Hz), 5.87 (d, *J* = 1.4 Hz), and 5.82 (d, *J* = 1.4 Hz)), two methoxyl groups (*δ* ~H~ 3.94 and 3.83), and two *N*-methyl groups (*δ* ~H~ 2.51 and 1.63). The ^13^C NMR (Table [1](#Tab1){ref-type="table"}) combined with the HSQC spectroscopic data identified twenty-eight aromatic, three methylenedioxyl, two methoxyl, two *N*-methyl, three methylene, and two sp^3^ methine carbons (Table [1](#Tab1){ref-type="table"}). Considered its molecular formula, one carbonyl carbon signal was absent in its ^13^C NMR spectrum. The above data suggested that **1** was a dimeric alkaloid consisting of a chelerythrine and a protopine moiety^[@CR5]^.Table 1^1^H \[600 MHz, *δ* in ppm, Mult. (*J* in Hz)\] and ^13^C NMR (150 MHz, *δ* in ppm) data of **1**--**3** in CDCl~3~. ^−a^No signal observed in ^1^H NMR and ^13^C NMR spectra.No.123*δ* ~H~ (mult., *J*, in Hz)*δ* ~C~*δ* ~H~ (mult., *J*, in Hz)*δ* ~C~*δ* ~H~ (multi, *J*, in Hz)*δ* ~C~17.05 (s)104.27.03 (s)104.17.01 (s)104.02147.5147.4147.23147.9148.0147.446.85 (s)100.86.77 (s)100.85.29 (br s)100.54a127.6127.8127.14b139.4139.4139.565.13 (d, 9.0)58.05.14 (d, 10.3)57.8^−a^63.86a126.7127.0125.67146.3146.3146.88152.1152.0152.196.68 (br d, 7.3)111.76.66 (br s)111.56.84 (d, 8.4)112.6107.23 (br d, 7.3)116.67.23 (br s)118.57.39 (d, 8.4)118.910a125.0125.0125.410b124.3124.5124.0117.61 (d, 8.5)119.87.63 (d, 8.5)119.97.78 (d, 8.4)119.8127.46 (d, 8.5)123.87.45 (d, 8.5)123.77.48 (d, 8.4)124.212a131.0130.8130.91′6.83 (s)111.76.92 (s)112.1^−a−a^2′145.6145.4^−a^3′148.3147.8^−a^4′6.21 (s)109.86.19 (s)109.75.89 (s)110.84′a133.7134.1^−a^5′2.37--2.31 (m) 1.93 (br s)33.42.50--2.33 (m) 1.86--1.65 (m)33.72.23--1.59 (m)^−a^6′2.37--2.31 (m) 1.85 (br s)56.92.50--2.33 (m) 1.86--1.65 (m)57.22.23--1.59 (m)^−a^8′3.07 (d, 13.2) 2.32 (br s)48.53.09 (d, 13.3) 2.50--2.33 (m)48.33.21 (br s) 3.02 (br s)^−a^8′a118.5130.6^−a^9′145.0147.0^−a^10′146.0150.5150.111′6.97 (br d, 8.0)107.17.07 (d, 8.3)110.86.81 (d, 6.6)107.712′7.50 (br s)122.57.61 (d, 8.3)125.27.83 (br s)^−a^12′a132.9132.1^−a^13′4.59 (d, 9.0)52.84.47(d, 10.3)52.95.01 (br s)^−a^14′^−a−a−a^14′a135.5135.6^−a^5-*N*-CH~3~2.51 (s)41.12.50 (s)40.82.56 (s)43.17′-*N*-CH~3~1.63 (s)41.71.49 (s)41.51.89 (s)41.42,3-OCH~2~O-5.99 (d, 1.1) 5.96 (d, 1.1)101.15.93--5.81 (m)101.05.99--5.76 (m)101.17-OCH~3~3.94 (s)61.03.93 (s)61.83.77 (s)61.18-OCH~3~3.83 (s)55.93.81 (s)55.73.65 (s)56.12′,3′-OCH~2~O-5.91 (d, 1.1) 5.83 (d, 1.1)101.15.93--5.81 (m)100.95.99--5.76 (m)101.69′,10′-OCH~2~O- or --OCH~3~5.87 (d, 1.4) 5.82 (d, 1.4)100.63.50 (s) 3.95 (s)60.9 56.05.99--5.76 (m)100.9

The HMBC correlations (Fig. [3](#Fig3){ref-type="fig"}) of H-1/C-3, C-4a, C-12; H-10/C-6a, C-8; H-11/C-4b, C-10a, C-12a; H-12/C-1, C-4a, C-10b; 7-OCH~3~/C-7; 8-OCH~3~/C-8; -*N*CH~3~/C-4b, and from the protons of OCH~2~O (*δ* ~H~ 5.99 and 5.96) to C-2, and C-3, as well as the^1^H−^1^H COSY correlations (Fig. [3](#Fig3){ref-type="fig"}) of H-9/H-10 and H-11/H-12, evidenced the presence of chelerythrine moiety. This was furthermore confirmed by the fragment peak at *m/z* 348.1281 in the HRESIMS/MS (Supplementary Figure [S13](#MOESM1){ref-type="media"}). In the ^1^H NMR spectra of **1**, the signals in the high field region were substantially overlapped. Hence, the presence of protopine structure could not be completely assigned with the observed HMBC cross-peaks of H-1′/C-3′, C-4′a; H-4′/C-2′, C-5′, C-14′a; H-11′/C-9′, C-10′, C-12′a; as well as cross-peaks of two methylenedioxys at *δ* ~H~ 5.91, 5.83/C-2′, C-3′ and *δ* ~H~ 5.87, 5.82/C-9′, C-10′. Comparison of the NMR and HRESIMS data of **1** with those of macleayins A and B^5^ which were previously obtained as a single crystal molecule from *M*. *cordata* indicated that **1** and macleayin B possessed protopine moiety. In addition, the^1^H-^1^H COSY of H-6/H-13′ proved the direct linkage of C6--C13′. Similarly, one carbonyl and several crucial HMBC correlations were not observed in **1**. Accordingly, the planar structure of compound 1 was defined as shown.Figure 3HMBC,^1^H-^1^H COSY, and NOESY correlations of macleayin F (**1**).

The relative stereochemistry of **1** was established by the NOESY experiment (Fig. [3](#Fig3){ref-type="fig"}). The coupling constant (*J* = 9.0 Hz) and no NOE correlation between H-6 and H-13′, suggested that H-6 and H-13′ may be on the opposite side. The proposed relative stereochemistry is a reasonable hypothesis, as well as the fact that this is due to the lacunar nature of the available data set. Compound **1** was a racemic mixture like macleayins A and B due to the lack of optical rotation and Cotton effect (CE)^[@CR7]^. Subsequently, the enantioseparation of **1** was performed on a chiral column (Daicel Chiralpak IB) to yield the enantiomers **1a** and **1b** in an approximate 1:1 ratio (Supplementary Figure [S4](#MOESM1){ref-type="media"})^[@CR8]^, which were opposite in terms of optical rotation (**1a**:$\documentclass[12pt]{minimal}
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                \begin{document}$${[\alpha ]}_{{\rm{D}}}^{{\rm{20}}}$$\end{document}$ + 274 (*c* 0.07, MeOH), **1b**: $\documentclass[12pt]{minimal}
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                \begin{document}$${[\alpha ]}_{{\rm{D}}}^{{\rm{20}}}$$\end{document}$ −248 (*c* 0.07, MeOH)). The assignments of their absolute configuration at the stereogenic centers were determined by comparing the ECD spectra (Fig. [4](#Fig4){ref-type="fig"}) of both enantiomers with those of two similar compounds (+)-macleayin A and (−)-macleayin A. The measured ECD curves of **1a** and **1b** matched with that of (6 *R*,13′*R*)-macleayin A and (6 *S*,13′*S*)-macleayin A, respectively. Hence, the absolute configuration for 1a (6 *R*,13′*R*) and **1b** (6 *S*,13′*S*) were unambiguously determined as shown in Fig. [1](#Fig1){ref-type="fig"} and named (+)-macleayin F and (−)-macleayin F, respectively.Figure 4CD spectra for compounds **1a**, **1b**, **2a**, **2b**, **3a**, **3b**, and (+)-/(−)-macleayin A, (+)-/(−)-macleayin B.

Macleayin G (**2**) was obtained as white amorphous powder. The molecular formula of **2** was established as C~42~H~40~N~2~O~9~ on the basis of positive HRESIMS at *m/z* 717.2799 \[M + H\]^+^ (calcd 717.2807), indicating 24 indices of hydrogen deficiency. The IR spectrum showed absorption bands due to ketone carbonyl (1652 cm^−1^), methylenedioxyl group (2794, 938 cm^−1^), and aromatic ring (1619, 1491, 1458 cm^−1^) functionalities. The UV spectrum exhibited maximum absorption at 229 and 286 nm. Its^1^H and ^13^C NMR data (Table [1](#Tab1){ref-type="table"}) revealed structural similarity to **1**, expected that one methylenedioxy in **1** was replaced by two methoxyl groups (*δ* ~H~ 3.95, 3.50; *δ* ~C~ 56.0, 60.9). It was confirmed by the HMBC correlations of 8-OCH~3~ with C-8, 7-OCH~3~/H-6 with C-7; 9′-OCH~3~/H-8′/H-11′ with C-9′, and of 10′-OCH~3~/H-11′ with C-10′ (Supplementary Figure [S2](#MOESM1){ref-type="media"}). Furthermore, the HRESIMS/MS showed the fragment ion peak at *m/z* 348.1306 which was recognized as chelerythrine, suggested that **2** was made up of chelerythrine and allocryptopine, which was supported by comparison of NMR data of **2** with those of macleayin B^[@CR5]^. ^1^H-^1^H COSY correlations (Supplementary Figure [S2](#MOESM1){ref-type="media"}) of H-6/H-13′ confirmed that two parts were connected by C-6 with C-13′. Similarly, compound **2** was proposed to be a racemic mixture on account of the lack of optical rotation and CE. Subsequently, **2a** and **2b** were obtained by chiral-phase HPLC separation in a ratio of 1:1 (Supplementary Figure [S5](#MOESM1){ref-type="media"}), which exhibited the mirror image-like ECD curves and owned the opposite specific optical rotations (**2a**: $\documentclass[12pt]{minimal}
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                \begin{document}$${[\alpha ]}_{{\rm{D}}}^{{\rm{20}}}$$\end{document}$ **−**210 (*c* 0.10 MeOH)). Thus, the absolute configuration of **2a** and **2b** were assigned as (6 *R*,13′*R*) and (6 *S*,13′*S*) by comparing their experimental ECD spectra with those of (+)-macleayin A and (**−**)-macleayin A (Fig. [4](#Fig4){ref-type="fig"}), and given the names (+)-macleayin G and (**−**)-macleayin G, respectively.

Macleayin H (**3**) was isolated as white amorphous powder and yielded a quasi-molecular ion peak at *m/z* 701.2485 \[M + H\]^+^ (calcd for 701.2494) in the HRESIMS, indicative of molecular formula C~41~H~36~N~2~O~9~, the same as that of **1**. The identical fragment peak at *m/z* 348.1323 in HRESIMS/MS as **1**, together with 1D and 2D NMR data (Table [1](#Tab1){ref-type="table"}) deduced that **3** was a similar dimer comprising chelerythrine and protopine as **1**. But the chemical shifts of H-4 and H-4′ in compound **3** were significantly shifted upfield (ca. −1.6 and −0.3 ppm), and H-13′ was shifted downfield (ca. +0.4 ppm). Compound **3** showed more similar NMR data (Supplementary Tables [S1](#MOESM1){ref-type="media"} and [S2](#MOESM1){ref-type="media"}) to macleayin B than **1**, deducing that the relative configuration of **3** was the same as macleayin B. Subsequent chiral HPLC resolution (Supplementary Figure [S6](#MOESM1){ref-type="media"}) of **3** afforded **3a** ($\documentclass[12pt]{minimal}
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                \begin{document}$${[\alpha ]}_{{\rm{D}}}^{{\rm{20}}}$$\end{document}$ −94 (*c* 0.11 MeOH)). The absolute configuration at the stereocenters of **3a** (6 *S*,13′*R*) and **3b** (6 *R*,13′*S*) were established by comparison of their experimental ECD spectra with those of (+)-macleayin B and (−)-macleayin A (Fig. [4](#Fig4){ref-type="fig"}), and named (+)-macleayin H, and (−)-macleayin H, respectively.

Antiproliferative activity {#Sec4}
--------------------------

Our previous study revealed that alkaloids from *M*. *cordata* exhibited promising antiproliferative effects, so all the isolated compounds were tested for the growth inhibitory activities against HL-60, A-549, MCF-7 human cancer cell lines by the trypan blue method and MTT method^[@CR9],[@CR10]^. The results were summarized in Table [2](#Tab2){ref-type="table"}. All compounds inhibited the growth against all the tested cancer cells with IC~50~ values ranged from 1.34 to 41.30 *μ*M. In particular, **1a**, **1b**, **2a**, and **2b** showed more potent antiproliferative property against HL-60 cell lines than their biogenetic precursors **5--7**, and the enantiomers displayed similar inhibitory effects. Therefore, compound **2** was selected for further investigation on the antiproliferative mechanism in HL-60 cells.Table 2The antiproliferative activity of compounds**1**--**7**. IC~50~ is the concentration that inhibited 50% of cell growth. Results are expressed as the mean ± SD of three independent experiments.Comp.IC~50~ (*μ*M)HL-60A-549MCF-71a1.70 ± 0.8910.98 ± 1.9325.78 ± 0.881b1.34 ± 1.022a3.35 ± 0.139.87 ± 1.0812.29 ± 1.062b2.47 ± 0.563a6.49 ± 1.2441.30 ± 0.2918.88 ± 0.993b8.37 ± 0.2647.71 ± 0.788.49 ± 0.635.51 ± 1.4259.61 ± 2.459.38 ± 0.917.74 ± 2.7568.94 ± 0.3727.37 ± 1.0525.19 ± 3.0977.18 ± 1.0326.06 ± 0.5828.24 ± 1.645-Fu2.8 ± 2.031.6 ± 1.2217.01 ± 0.95

Influence of compound 2 on the HL-60 cell cycle {#Sec5}
-----------------------------------------------

Cell cycle arrest was an important sign for inhibition of proliferation and the series of events that took place in a cell leading to its division and duplication^[@CR11],[@CR12]^. In order to explore whether the growth inhibition induced by **2** was caused by the regulation of the HL-60 cell cycle, the cell cycle distribution in the presence of **2** was detected by flow cytometry (Fig. [5](#Fig5){ref-type="fig"}). HL-60 cells were treated with compound **2** at concentrations of 3.75, 7.5, and 15.0 *μ*M for 72 h, which resulted in a remarkable increase of 31.49%, 46.11%, and 48.36% of cells at S phase compared with that of the control (28.00%), while there was a concomitant decline in the number of cells in G1 and G2 phases. This information indicated that compound **2** influenced cell cycle of HL-60 arrested at S phase in a dose-dependent manner.Figure 5The influence of HL-60 cell cycle by compound **2**. Left red part: cell in G1 phase; Right red part: cell in G2 phase; Oblique line part: cell in S phase; White part: total cells.

Induction of apoptosis by compound 2 {#Sec6}
------------------------------------

Apoptosis is an ordered and orchestrated cellular process that takes play in physiological and pathological conditions^[@CR13],[@CR14]^. Therefore, drug-induced apoptosis in tumor cells is important for cancer treatment. The effects of **2** on the apoptosis of HL-60 cells by staining them with Annexin-V APC/7-AAD and analysis by flow cytometry were examined. As shown in Fig. [6](#Fig6){ref-type="fig"}, the treatment with 3.75, 7.50, and 15.0 *μ*M of **2** for 72 h in HL-60 cells, the total percentage of early apoptotic cells (right low quadrant) and late apoptotic and necrotic cells (right upper quadrant) were increased from 5.41% to 61.34%. The data indicated that compound **2** remarkable induced apoptotic cells death in HL-60 cells in a concentration-dependent manner.Figure 6Induction of apoptosis by**2** in HL-60 cells.

Effect of mitochondria depolarization by compound 2 {#Sec7}
---------------------------------------------------

The destruction of mitochondrial membrane potential is widely considered to be a crucial event in the process of cell apoptosis^[@CR15],[@CR16]^. In order to further research the apoptosis induced effect of compound **2**, the fluorescent probe JC-1 was carried out to detect the changes of mitochondrial membrane potential. JC-1 (a kind of lipophilic cationic dye) can pass the plasma membrane into cells and accumulate in mitochondria. Meanwhile, membrane potential and degree of accumulation of JC-1 in mitochondria exist close contact. Normal cells, normal membrane potential, at the higher concentration of dye JC-1, with the dye aggregation, fluorescence emission gradually changes red. While apoptotic cells, the mitochondrial transmembrane potential depolarization, the monomer of JC-1 is formed, and fluorescence emission changes from red to green. Therefore, it can easily be used to test the changes of mitochondrial membrane potential by detecting the changes of fluorescence color. HL-60 cells dealt with compound **2** at 3.75, 7.50, and 15 *μ*M for 72 h respectively were stained with JC-1, meanwhile untreated cells was used as control. The percentage of green fluorescence increased (0.12%, 25.11%, 36.70%, and 64.80%) in a concentration-dependent manner was observed in Fig. [7](#Fig7){ref-type="fig"}. The results demonstrated that **2** could induce apoptosis in HL-60 cells through mitochondrial-related pathway.Figure 7Effect of **2** on the mitochondrial membrane potentials in HL-60 cells.

Methods {#Sec8}
=======

General experimental procedures {#Sec9}
-------------------------------

Optical rotations were measured on Rudolph Autopol-V digital polarimeter and Jasco P-2000 polarimeter. UV spectra were recorded using a Shimadzu UV-2201 spectrometer. IR spectra were recorded on a Bruker IFS-55 spectrometer (using a KBr disk method). ECD spectra were measured on Bio-logic MOS 450 spectropolarimeter. 1D and 2D NMR spectra were acquired with Bruker ARX-300 and AV-600 NMR spectrometers using solvent signals (CDCl~3~: *δ* ~H~ 7.26/*δ* ~C~ 77.16; CD~3~OD: *δ* ~H~ 3.31/*δ* ~C~ 49.00), with tetramethylsilane (TMS) as an internal standard. HRESIMS data were obtained using Bruker micro-TOFQ-Q mass spectrometer. LC-MS analysis was performed with Thermo Fisher LCQ Fleet Ion Trap LC/MS^n^, and ESI-IT-MS spectra were performed on a Thermo LCQ Advantage MAX Fleet mass spectrometer. A Shimadzu LC-6 AD equipped with a SPD-20A (UV/DAD) detector was used for HPLC. The chiral HPLC isolation was accomplished on Daicel Chiralpak IB column (4.6 × 250 mm, 5 *μ*m; Daicel Chemical Ltd, Tokyo, Japan). Column chromatography (CC) were performed with silica (100--200 and 200--300 mesh, Qingdao Haiyang Chemical Co., Ltd., Qingdao, China), neutral alumina (100--200 mesh, Sinopharm Chemical Reagent Co. Ltd., Shanghai, China), ODS (50 *µ*m, YMC Co. Ltd., Kyoto, Japan), and Sephadex LH-20 (GE Healthcare, Sweden). TLC analyses were carried out with glass plate precoated silica gel (GF~254~, Qingdao Haiyang Chemical Co., Ltd., Qingdao, China). Spots were visualized under UV light or by spraying with 10% H~2~SO~4~ in 95% EtOH followed by heating or with bismuth potassium iodide solution.

Plant materials {#Sec10}
---------------

The plant material was purchased from Anguo Medicines Ltd (Hebei), China, in November 2013, and was identified as the aerial parts of *Macleaya cordata* (Willd.) R. Br. by Prof. Jincai Lu (School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China). The voucher sample (BLH-20131108) was deposited in the Department of Natural Products Chemistry, Shenyang Pharmaceutical University, Shenyang, China.

Extraction and isolation {#Sec11}
------------------------

The air-dried aerial parts of *M*. *cordata* (40.0 kg) were extracted with 95% ethanol (400 L) under reflux 2 times, and 75% ethanol (1 × 400 L), each time for 2 h, respectively. After the solvent was removed under reduced pressure, the crude extract (14.6 kg) was suspended in H~2~O, successively partitioned with CH~2~Cl~2~ and *n*-BuOH, to afford CH~2~Cl~2~, *n*-BuOH and aqueous extracts. Part of the CH~2~Cl~2~ extract (500 g) was subjected to silica gel column chromatography (CC) and eluted with petroleum ether (60--90 °C) --acetone (100:5, 100:10, 100:20, 100:50, 1:1 and 0:100, v/v) to yield six crude fractions (Fr. A-- Fr. F). Fr. A was subsequently loaded onto a silica gel column using petroleum ether--EtOAc (100:0, 100:3, 100:5, 100:8, 100:20, v/v) as the eluent to give five subfractions (Fr. A1 --Fr. A5). Fr. A2 was applied to neutral alumina CC eluting with petroleum ether--EtOAc, and further purified by preparative TLC (PTLC) to afford **4** (4.0 mg). Fr. D was further subjected to ODS CC with MeOH--H~2~O (50:50, 60:40, 65:35, 70:30, 80:20, 90:10, v/v) as the mobile phase to give subfractions (Fr. D1-Fr. D6). The residue of Fr. D1 and Fr. D4 after recrystallization was separated by Sephadex LH-20 CC eluting with CH~2~Cl~2~/MeOH (1:1, v/v) to yield total alkaloids (23.9 g) based on TLC analysis. The total alkaloids fraction was further subjected to ODS CC (MeOH--H~2~O, 30:70 to 90:10, v/v). The fraction of 40% methanol elution was recrystallized to give **5** (4.5 mg). The fraction of 75% methanol elution was separated by performing repeated neutral alumina, silica gel, Sephadex LH-20 CC, and PTLC to yield **1** (5.0 mg), and **3** (7.5 mg). Fr. E was subjected to silica gel CC eluted with CH~2~Cl~2~--MeOH (100:0, 200:1, 100:1, 100:2, v/v) to afford four subfractions Fr. E1--Fr. E4. Fr. E1 was subjected to ODS CC eluting with MeOH--H~2~O gradient system, and further recrystallization to yield **6** (30 mg), and then performed on Sephadex LH-20 CC eluting with CH~2~Cl~2~/MeOH (1:1, v/v) to afford **2** (6.0 mg). The *n*-BuOH extract (185 g) was separated on macroporous resin (D101) using EtOH--H~2~O (30:70, 50:50, 70:30, 95:5, v/v) as the eluent to give four subfractions Fr. G--Fr. J. Fr. H was subjected to ODS CC with MeOH--H~2~O gradient eluting, and the part of 20% MeOH eluting was further purified by reversed-phase preparative HPLC (ODS; 5 *μ*m, 250 × 20 mm; MeOH/H~2~O/DEA, 63:37:0.05, v/v/v; flow rate, 5.0 mL/min) to afford **7** (35 mg, *t* ~R~ = 45 min).

Chiral separation of **1**, **2**, and **3** was performed on Daicel chiralpak IB column (250 × 4.6 mm), eluted with *n*-hexane--EtOH--DEA (40: 60: 0.1, v/v/v), flow rate 1.0 mL/min to yield **1a** (1.1 mg, t~R~ 5.930 min), **1b** (1.1 mg, *t* ~R~ 8.022 min), **2a** (1.5 mg, *t* ~R~ 5.813 min), **2b** (1.5 mg, *t* ~R~ 12.305 min), **3a** (1.7 mg, *t* ~R~ 12.087 min), and **3b** (1.7 mg, *t* ~R~ 8.074 min), respectively.

Macleayin F (**1**). White amorphous powder. UV (CH~2~Cl~2~) *λ* ~max~ (log *ε*): 227 (4.6), 287 (4.6) nm. IR (KBr) *ν* ~max~: 2790, 1656, 1616, 1486, 1462, 941 cm^−1^. (+)-HRESIMS *m/z* 701.2491 \[M + H\]^+^ (calcd for C~41~H~37~N~2~O~9~, 701.2494).

(+)-Macleayin F (**1a**). $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${[\alpha ]}_{{\rm{D}}}^{{\rm{20}}}$$\end{document}$ + 274 (*c* 0.07, MeOH); ECD (MeOH) *λmax* (*∆ɛ*) 224 (+9.4), 243 (−22.6), 268 (−3.9), 300 (−7.9) nm.

(−)-Macleayin F (**1b**). $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${[\alpha ]}_{{\rm{D}}}^{{\rm{20}}}$$\end{document}$ −248 (*c* 0.07, MeOH); ECD (MeOH) *λmax* (*∆ɛ*) 221 (−13.5), 243 (+24.8), 269 (+3.4), 300 (+7.5) nm.

Macleayin G (**2**). White amorphous powder. UV (CH~2~Cl~2~) *λ* ~max~ (log *ε*): 229 (4.6), 286 (4.6) nm. IR (KBr) *ν* ~max~: 2794, 1652, 1619, 1491, 1458, 938 cm^−1^. (+)-HRESIMS *m/z* 717.2799 \[M + H\]^+^ (calcd for C~42~H~41~N~2~O~9~, 717.2807).

(+)-Macleayin G (**2a**). $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${[\alpha ]}_{{\rm{D}}}^{{\rm{20}}}$$\end{document}$ + 238 (*c* 0.10, MeOH); ECD (MeOH) *λ* ~max~ (*∆ɛ*) 222 (+15.9), 241 (−30.3), 264 (−6.8), 283 (−14.3) nm.

(−)-Macleayin G (**2b**). $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${[\alpha ]}_{{\rm{D}}}^{{\rm{20}}}$$\end{document}$ −210 (*c* 0.10, MeOH); ECD (MeOH) *λ* ~max~ (*∆ɛ*) 223 (−19.4), 241 (+36.0), 265 (+7.3), 283 (+15.1) nm.

Macleayin H (**3**). White amorphous powder. UV (MeOH) *λ* ~max~ (log *ε*): 232 (4.6), 287 (4.6) nm. IR (KBr) *ν* ~max~: 2798, 1658, 1617, 1485, 1463, 939 cm^−1^. (+)-HRESIMS *m/z* 701.2485 \[M + H\]^+^ (calcd for C~41~H~37~N~2~O~9~, 701.2494).

(+)-Macleayin H (**3a**). $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${[\alpha ]}_{{\rm{D}}}^{{\rm{20}}}$$\end{document}$ + 71 (*c* 0.11, MeOH); ECD (MeOH) *λ* ~max~ (*∆ɛ*) 204 (+19.3), 233 (−24.0), 271 (−0.2), 291 (−5.7) nm.

(−)-macleayin H (**3b**). $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${[\alpha ]}_{{\rm{D}}}^{{\rm{20}}}$$\end{document}$ −94 (*c* 0.11, MeOH); ECD (MeOH) *λ* ~max~ (*∆ɛ*) 205 (−17.2), 233 (+19.3), 276 (+0.4), 291 (+6.0) nm.

Sanguinarine (**4**). Red amorphous powder. ^1^H NMR (400 MHz, CD~3~OD) *δ* ~H~: 9.97 (1 H, s, H-6), 8.67 (1 H, d, *J* = 8.8 Hz, H-10), 8.57 (1 H, d, *J* = 8.9 Hz, H-11), 8.25 (1 H, d, *J* = 8.9 Hz, H-12), 8.18 (1 H, s, H-4), 7.98 (1 H, d, *J* = 8.8 Hz, H-9), 7.60 (1 H, s, H-1), 6.54 (2 H, s, -OCH~2~O-2,3), 6.28 (2 H, s, -OCH~2~O-7,8), 4.97 (3 H, s, *N*-CH~3~). ^13^C NMR (150 MHz, CD~3~OD) *δ* ~C~: 107.0 (C-1), 150.8 (C-2), 150.9 (C-3), 105.0 (C-4), 122.0 (C-4a), 132.9(C-4b), 52.8 (*N*-CH~3~), 151.0 (C-6), 111.4 (C-6a), 148.3 (C-7), 149.6 (C-8), 121.3 (C-9), 118.3 (C-10), 129.2 (C-10a), 127.7 (C-10b), 119.7 (C-11), 133.3 (C-12), 134.3 (C-12a), 104.3 (-OCH~2~O-2,3), 106.5 (-OCH~2~O-7,8).

Chelerythrine (**5**). Yellow amorphous powder. ^1^H NMR (400 MHz, CD~3~OD) *δ* ~H~: 9.99 (1 H, s, H-6), 8.71 (1 H, d, *J* = 9.0 Hz, H-10), 8.68 (1 H, d, *J* = 9.2 Hz, H-11), 8.24 (1 H, d, *J* = 9.0 Hz, H-9), 8.23 (1 H, d, *J* = 9.2 Hz, H-12), 8.21 (1 H, s, H-4), 7.59 (1 H, s, H-1), 6.28 (2 H, s, -OCH~2~O-2,3), 4.30 (3 H, s, 7-OCH~3~), 4.15 (3 H, s, 8-OCH~3~), 5.01 (3 H, s, *N*-CH~3~). ^13^C NMR (100 MHz, CD~3~OD) *δ* ~C~: 107.1 (C-1), 151.8 (C-2), 150.8 (C-3), 105.1 (C-4), 121.9 (C-4a), 132.6 (C-4b), 52.9 (*N*-CH~3~), 152.1 (C-6), 119.9 (C-6a), 147.6 (C-7), 151.8 (C-8), 127.5 (C-9), 121.0 (C-10), 130.2 (C-10a), 127.2 (C-10b), 119.5 (C-11), 132.7 (C-12), 134.4 (C-12a), 104.3 (-OCH~2~O-2,3), 62.8 (7-OCH~3~), 57.6 (8-OCH~3~).

Protopine (**6**). Colourless tetragonal crystal (CH~2~Cl~2~: MeOH = 1:1). ^1^H NMR (400 MHz, CDCl~3~) *δ* ~H~: 6.90 (1 H, s, H-1), 6.69 (1 H, d, *J* = 7.8 Hz, H-12), 6.66 (1 H, d, *J* = 7.8 Hz, H-11), 6.64 (1 H, s, H-4), 5.95 (2 H, s, -OCH~2~O-2,3), 5.92 (2 H, s, -OCH~2~O-9,10), 3.78 (2 H, br s, H-13), 3.58 (2 H, br s, H-8), 2.2--3.2 (4 H, br s, H-5, 6), 1.91 (3 H, s, *N*-CH~3~). ^13^C NMR (100 MHz, CDCl~3~) *δ* ~C~:108.3 (C-1), 146.5 (C-2), 148.1 (C-3), 110.6 (C-4), 132.9 (C-4a), 31.9 (C-5), 57.9 (C-6), 50.9 (C-8), 118.0 (C-8a),146.0 (C-9), 146.1 (C-10), 106.9 (C-11), 125.2 (C-12), 129.1 (C-12a), 46.6 (C-13), 195.1 (C-14), 136.3 (C-14a), 101.3 (-OCH~2~O-2,3), 101.0 (-OCH~2~O-9,10), 41.6 (*N*-CH~3~).

Allocryptopine (**7**). White amorphous powder. ^1^H NMR (400 MHz, CDCl~3~) *δ* ~H~: 6.95 (1 H, s, H-1), 6.91 (1 H, d, *J* = 8.2 Hz, H-12), 6.80 (1 H, d, *J* = 8.2 Hz, H-11), 6.63 (1 H, s, H-4), 5.94 (2 H, s, -OCH~2~O-2,3), 3.86 (3 H, s, 10-OCH~3~), 3.78 (3 H, s, 9-OCH~3~), 3.73 (2 H, br s, H-13), 3.0−3.4 (2 H, br s, H-8), 2.2−3.0 (4 H, br s, H-5, 6), 1.86 (3 H, s, *N*-CH~3~). ^13^C NMR (100 MHz, CDCl~3~) *δ* ~C~: 110.6 (C-1), 146.2 (C-2), 148.2 (C-3), 109.4 (C-4), 136.2 (C-4a), 32.5 (C-5), 57.7 (C-6), 50.3 (C-8), 128.7 (C-8a), 151.7 (C-9), 147.6 (C-10), 110.8 (C-11), 127.9 (C-12), 129.8 (C-12a), 46.5 (C-13), 193.5 (C-14), 133.0 (C-14a), 101.3 (-OCH~2~O-2,3), 60.9 (9-OCH~3~), 55.8 (10-OCH~3~), 41.4 (*N*-CH~3~).

Antiproliferative activity {#Sec12}
--------------------------

The HL-60 (human leukaemia cell lines), MCF-7 (human breast cancer cell lines), A-549 (human lung adenocarcinoma cell lines) used in this study were purchased from America Type Culture Collection, ATCC (Rockville, MD, USA). All were cultured in RPMI-1640 medium (Gibco, New York, NY, USA) supplemented with 100 U/mL penicillin, 100 *μ*g/mL streptomycin, 1 mM glutamine and 10% heat-inactivated fetal bovine serum (Gibco) at 37 °C in humidified atmosphere with 5% CO~2~. Cytotoxic activity was evaluated by the trypan blue method against HL-60, and MTT assay against MCF-7 and A-549.

Cell cycle study {#Sec13}
----------------

HL-60 cells in logarithmic growth were plated in 6-well plates and incubated for 24 h, then incubated with different concentrations (0, 3.75, 7.50, 15.0 *μ*M) of **2** (DMSO only as control) at 37 °C for 72 h. The cells were washed with ice-cold PBS buffer, and then collected, fixed with 70% EtOH at −4 °C for 24 h. The fixed cells were washed with ice-cold PBS and then were treated with 100 *μ*L RNase A at 37 °C for 30 min, and finally stained with 400 *μ*L propidium iodide (PI) in the dark at 4 °C for 30 min. The cycle distribution analysis was performed using a flow cytometer (FACS Calibur, Becton-Dickinson, America).

Cell apoptosis analysis {#Sec14}
-----------------------

HL-60 cells in logarithmic growth were plated in 6-well plates and incubated for 24 h, then incubated with different concentrations (0, 3.75, 7.50, 15.0 *μ*M) of **2** (DMSO only as control) at 37 °C for 72 h. The cells were washed twice with ice-cold PBS buffer, and then collected. 500 *μ*L binding buffer suspension cells were added, and finally double stained Annexin V--APC/7-AAD at room temperature for 15 min in the dark. The apoptotic cells were detected to analyze apoptosis by flow cytometry.

Mitochondrial membrane potential assay {#Sec15}
--------------------------------------

HL-60 cells in logarithmic growth were plates in 6-well and incubated for 24 h, then incubated with different concentrations (0, 3.75, 7.50, 15.0 *μ*M) of **2** (DMSO only as control) at 37 °C for 48 h. The cells were washed with ice-cold PBS buffer, subsequently collected and adjusted the cells concentration to 1 × 10^6^/ml, and finally stained according to the manufacture's instruction (Keygen, KGA601, Nanjing, China) with JC-1. The percentage of green fluorescence was detected by the flow cytometry to analyze the cells apoptosis and collapsed mitochondrial membrane potentials.
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